本帖最后由 老马 于 2012-1-13 21:20 编辑
5 }, k6 g# B5 ?1 ]5 P# j) s# C7 H' E) s
爱必妥和阿瓦斯丁的比较
$ L% O+ M0 x! C' {8 l% z) b
- t. ~0 V' `+ ?6 `# a
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/* o- J) x: D/ G' D# j+ ]6 `$ J/ H, @4 }
4 E+ n- `: M2 S( `
6 c9 u) X) B9 F) f# i8 D. E
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/+ H# h6 Z C$ e6 B, _! m
==================================================3 s9 B+ Y0 ?1 S' y' s0 b
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)$ ^' S# Z0 J ~& `$ U; E
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.2 M5 U8 w" B. [( q
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
$ ?& X4 Y! p$ r2 X4 a1 h4 [
|
显身卡
